Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
These abstracts report on the company's three lead drug candidates, including olverembatinib
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Launch of 20 new medicines expected by 2030
Subscribe To Our Newsletter & Stay Updated
